Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BDB202301

Viscous Gel Temozolomide

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: Viscous Gel Temozolomide
    Indications: Glioblastoma
    Research phase: Phase I
    Cooperation demands: license-out or co-development Globally except in CIA
  • Highlights

    1. Superior Efficacy: Local injection increase TMZ concentration in the targeted brain tissue


    Viscous Gel Temozolomide


    1) In a mouse glioblastoma model, the asset reduces tumor size even before starting radiation therapy and systemic TMZ administration.


    2) Local injection of the novel formulation dramatically enhances tumor growth inhibition compared to radiation + systemic TMZ by 34%


    2. Superior Safety: local injection limits unnecessary systemic exposure to TMZ


    1) Gel formulation offers superior local concentration for tumor inhibition with decreased risk of systemic side effects.


    2) TMZ plasma/brain ratios are only 0.1%–4% indicating retention of drug intracranially.


    3. Superior MoA:


    TMZ therapy is known to depend on the methylation status of the O6-methylguanine-DNA methyltransferase gene (MGMT) promoter, the current data shows that local application for the target asset is independent of the methylation status of the MGMT promoter, which provides better coverage of patients with different types of GBM.


  • Project Introduction

    1. Asset type: Viscous Gel Temozolomide

    2. Indication: Glioblastoma

    3. Modality: Small molecule

    4. Research: Ready to start phase 1 (improved variant of Temodex®)

    5. Demands: License-out or co-development

    6. Research progress: Clinical trials completed in CIS region and registered as first-line treatment of glioblastoma

    Research progress:

    1) Clinical trials completed in CIS region and registered as first-line treatment of glioblastoma

    2) Clinical trial data shows increased patient’s life for more than 9 months

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message